Guidance

PCV (13-valent, adsorbed): patient group direction (PGD) template

PGD template to support the national pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV) vaccination programme.

Documents

PCV (13-valent, adsorbed): patient group direction (PGD) template

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

PCV (13-valent, adsorbed): notice of extension of PGD

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template is to support the national pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV) vaccination programme for individuals from 8 weeks to under 2 years of age. It is valid from 1 February 2016 to 31 January 2018.

PHE has published a notice of extension of PGD validity. Organisations may use this to extend the validity of this PGD until 31 January 2019 or until such time as PCV PGD v02.00 becomes valid, whichever is the earlier.

The PGD template requires further authorisation by a clinical governance or patient safety lead, who has designated responsibility for signing PGDs on behalf of NHS England for their geographical area. The PGD is not legal or valid without this local, formal authorisation.

The authorising commissioning body and providers are responsible for the adoption and governance of the use of this PGD.

Provider organisations, health professionals and immunisation practitioners should check they are working to the current PGD versions and only work to a legally authorised PGD from their commissioning body

These PGDs should be used with reference to the Green Book, and summary of product characteristics for the vaccine.

Published 4 February 2016
Last updated 10 January 2018 + show all updates
  1. Added notice of extension for PCV (13-valent, adsorbed) patient group direction.
  2. First published.